enVVeno Medical Corporation (NVNO) earnings
NVNO earnings moved a median of +1.49% by the close. Quarterly and annual NVNO reports and results, each read against the price at its own news timestamp. Back to the NVNO overview →
22 measured NVNO earnings events.
Where these NVNO earnings landedvs 22 measured NVNO earnings reactions
| Middle 50% of NVNO earnings reactions | -0.56% to +6.80% |
|---|---|
| Median reaction (to close) | +1.49% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 NVNO earnings events with a measured close landed between -0.56% and +6.80%; 64% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve | Press release | — | +0.76% | |
| Form 10-Q enVVeno Medical Corp For: Jun 30 | SEC filing · Form 10-Q | — | +0.76% | |
| enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System | Press release | — | +1.49% | |
| Form 10-Q enVVeno Medical Corp For: Mar 31 | SEC filing · Form 10-Q | — | +1.49% | |
| Form 10-K enVVeno Medical Corp For: Dec 31 | SEC filing · Form 10-K | +0.00% | +1.83% | |
| enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -3.92% | +8.71% | |
| Form 10-Q enVVeno Medical Corp For: Sep 30 | SEC filing · Form 10-Q | -3.92% | +8.71% | |
| enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +1.86% | +6.80% | |
| Form 10-Q enVVeno Medical Corp For: Jun 30 | SEC filing · Form 10-Q | +1.86% | +6.80% | |
| enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 | Press release | +2.66% | +9.97% | |
| Form 10-Q enVVeno Medical Corp For: Mar 31 | SEC filing · Form 10-Q | +2.66% | +9.97% | |
| Form 10-K enVVeno Medical Corp For: Dec 31 | SEC filing · Form 10-K | +23.43% | +20.91% | |
| Form 10-K/A enVVeno Medical Corp For: Dec 31 | SEC filing · Form 10-K | +0.30% | -9.12% | |
| enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year | Press release | +0.31% | +3.06% | |
| Form 10-Q enVVeno Medical Corp For: Sep 30 | SEC filing · Form 10-Q | +0.31% | +3.06% | |
| enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | -0.56% | |
| Form 10-Q enVVeno Medical Corp For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -0.56% | |
| enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | -2.74% | |
| Form 10-Q enVVeno Medical Corp For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.74% | |
| Form 10-K enVVeno Medical Corp For: Dec 31 | SEC filing · Form 10-K | -4.31% | -0.31% | |
| enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +0.00% | -1.15% | |
| Form 10-Q enVVeno Medical Corp For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.15% |
Keep exploring
More NVNO: analyst actions → · SEC filings → · NVNO overview →